Literature DB >> 10233397

Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation.

Y Maeda1, T Teshima, M Yamada, K Shinagawa, S Nakao, Y Ohno, K Kojima, M Hara, K Nagafuji, S Hayashi, S Fukuda, H Sawada, K Matsue, K Takenaka, F Ishimaru, K Ikeda, K Niiya, M Harada.   

Abstract

Herpesviruses frequently cause serious complications after allogeneic bone marrow transplantation (allo-BMT). Recent studies have shown more rapid immune reconstitution after allogeneic peripheral blood stem cell transplantation (allo-PBSCT) compared with allo-BMT. However, it has not been clarified whether the improved immune reconstitution after allo-PBSCT is associated with a lower incidence of herpesvirus infections. We monitored the emergence of Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 6 (HHV-6) and HHV-7 DNA by a nested-double polymerase chain reaction in peripheral blood leucocytes from 22 allo-BMT and 16 allo-PBSCT patients. Each virus had an unique temporal profile of detection. HHV-6 DNA was detected most frequently at 3 weeks after transplantation, whereas CMV and EBV DNA were detected later (2-3 months). Detection rates of HHV-6 DNA at 3 and 4 weeks after allo-BMT were significantly higher than those after allo-PBSCT (9/16 v 2/13 at 3 weeks, P < 0.01; 10/21 v 1/15 at 4 weeks, P < 0.01). Detection rates of the other three herpesviruses after the two types of allogeneic transplantation were not significantly different throughout observation period. Furthermore, detection of HHV-6 DNA within the first 4 weeks was associated with delayed platelet engraftment after both allo-BMT and allo-PBSCT (P < 0.01). These results suggest an advantage for allo-PBSCT over allo-BMT in terms of suppression of HHV-6 reactivation and prevention of subsequent complications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233397

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin.

Authors:  Amanda L Olson; Parastoo B Dahi; Junting Zheng; Sean M Devlin; Marissa Lubin; Anne Marie Gonzales; Sergio A Giralt; Miguel-Angel Perales; Esperanza B Papadopoulos; Doris M Ponce; James W Young; Nancy A Kernan; Andromachi Scaradavou; Richard J O'Reilly; Trudy N Small; Genovefa Papanicolaou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-16       Impact factor: 5.742

Review 3.  Human herpesvirus 6 and human herpesvirus 7: emerging pathogens in transplant patients.

Authors:  Duncan A Clark
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.319

4.  High incidence of Epstein-Barr virus, cytomegalovirus and human herpesvirus 6 infections in children with cancer.

Authors:  Jaroslav Michálek; Radek Horvath
Journal:  BMC Pediatr       Date:  2002-01-10       Impact factor: 2.125

5.  Human Herpesvirus-6 Pneumonitis around the Engraftment of Cord Blood Transplantation following Foscarnet Prophylaxis in a Patient with Acute Leukemia.

Authors:  Takashi Ishio; Tomoyuki Endo; Kohei Okada; Akio Shigematsu; Satoshi Hashino; Takanori Teshima
Journal:  Case Rep Hematol       Date:  2015-01-11

Review 6.  A complex interaction between drug allergy and viral infection.

Authors:  Tetsuo Shiohara; Yoko Kano
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 10.817

7.  Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Tuan L Phan; Kristen Carlin; Per Ljungman; Ioannis Politikos; Vicki Boussiotis; Michael Boeckh; Michele L Shaffer; Danielle M Zerr
Journal:  Biol Blood Marrow Transplant       Date:  2018-04-21       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.